Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00413075 · ClinicalTrials.gov registry record · Phase 1
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
A Phase 1 study, sponsored by Valerio Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 121
- Enrollment target
NCT00413075 is a Phase 1 study that has completed, run by Valerio Therapeutics. The registered enrollment target is 121 participants.
The verdict
NCT00413075, a Phase 1 study, has completed, sponsored by Valerio Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 121 participants
- Enrollment target
Study Summary
This is a Phase I dose escalation study of PXD101 administered orally. Oral belinostat will be given once or twice daily at various dosing schedules to patients with solid tumors. Doses will be escalated until the maximum tolerated dose (MTD) is identified. In parallel, a cohort of lymphoma patients will be given oral belinostat on a discontinuous once daily dosing schedule.
Interventions
- DRUG oral belinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2006-06 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00413075
The ClinicalTrials.gov registry entry for NCT00413075 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Valerio Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which oral belinostat is the first listed.
NCT00413075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00413075 about?
NCT00413075 is a clinical study titled "Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma". This is a Phase I dose escalation study of PXD101 administered orally. Oral belinostat will be given once or twice daily at various dosing schedules to patients with solid tumors. Doses will be escalated until the maximum tolerated dose (MTD) is identified. In parallel, a cohort of lymphoma patients...
What is the current status of trial NCT00413075?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 121 participants. The study started on 2006-06. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00413075?
The interventions under investigation include: oral belinostat (DRUG).
Who is sponsoring clinical trial NCT00413075?
This trial is sponsored by Valerio Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.